The Impact of Phosphate Metabolism on Healthy Aging

Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).

CT.gov Identifier
NCT03771105
EudraCT Identifier
N/A
CTIS:
N/A
Sponsor
Yale University
Collaborator
National Center for Advancing Translational Sciences (NCATS)
Study Contact Information
N/A
Recruiting
Contact Us

Study Details

Diseases
Alport syndrome
Study Drug
Phosphate
Genes
COL4A4
COL4A3
Study Dates
Jan 2019 - Apr 2028
Sex
Female & Male
Age
13+ years
Inclusion and Exclusion Criteria
Inclusion Criteria:
  • * Children above the age of 13 years
  • * Younger and older adults with XLH and HHRH with confirmed NPT2c mutations affecting both copies of the NPT2c gene (HHRH) or one copy of the PHEX gene (XLH)
  • * Be willing to provide access to prior medical records to determine eligibility including imaging, biochemical, medical, and surgical history data
  • * Be willing and able to complete all aspects of the study
  • * Be willing to adhere to the study visit schedule and comply with the assessments (in the opinion of the investigator).
Exclusion Criteria:
  • Subjects will be excluded, if they are children younger than age 13 years
  • * Subjects that have other diseases likely to impact bone and mineral metabolism (e.g. renal, hepatic, gastrointestinal disorders, and malignancy),
  • * Subjects that are currently pregnant,
  • * Subjects that received medical therapy or developed any condition, which in the opinion of the investigator, could present a concern for either subject safety or difficulty with data interpretation.
  • * Subjects will be excluded from Aim 2, if they are unable to tolerate supplemental phosphate.

Protocol Summary

Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.